Effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic

Mar 01, 2011

Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine

A new study from Stanford researchers published in PLoS Medicine makes the case that a combination of methadone and anti-retroviral treatment would have the greatest effect on reducing new infections and improving quality of life in a region where HIV is spreading rapidly among intravenous drug users.

In the past decade, an epidemic of HIV has swept through Ukraine, fueled mostly by intravenous drug use. Of Ukraine's approximately 390,000 intravenous drug users as many as half are HIV-infected. Researchers at Stanford and Veterans Affairs Palo Alto Health Care System have demonstrated, using a modeling study, that the most effective way to combat the spreading disease is a combined program of drug substitution – providing for opiate users, for instance – and anti-retroviral therapy for those already infected with HIV.

"HIV is spreading in Eastern Europe more quickly than in any other part of the world," said Margaret Brandeau, the Coleman F. Fung Professor of Engineering at Stanford University and senior author of the study. "Our study shows that substitution therapy for injection drug users is an inexpensive and effective means of curbing HIV transmission in the region."

With no further intervention, the study predicts that HIV prevalence will reach 67.2 percent in intravenous drug users in 20 years. The authors further show that providing drug-substitution to just 25 percent of intravenous drug users today could lower that figure considerably.

"Not only does drug substitution therapy work, but it is remarkably cost-effective when you consider total costs of treating and caring for a growing HIV-infected community," said lead author Sabina Alistar.

"Providing effective drug substitution therapy and antiretroviral therapy together to the injection-drug-using community protects the entire population – it actually prevents more infections in non-drug users than in the drug-using community," said Douglas K. Owens, co-author and a senior investigator at the VA Palo Alto and professor of medicine at Stanford University.

Explore further: Researchers look at prescription opioid abuse among young adults in NYC

More information: Alistar SS, Owens DK, Brandeau ML (2011) Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine. PLoS Med 8(3): e1000423. doi:10.1371/journal.pmed.1000423

add to favorites email to friend print save as pdf

Related Stories

Injecting drug users have poor access to HIV services

Feb 28, 2010

The provision of HIV prevention services for injecting drug users, which is essential to contain the spread of HIV, is inadequate in most countries around the world and presents a critical public health problem, according ...

Increased HAART coverage associated with 50 percent drop

Feb 18, 2010

A comprehensive population-based study, conducted by the BC Centre for Excellence in HIV/AIDS (BC-CfE) and presented at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco, shows that expanded ...

Recommended for you

South Africa's life expectancy jumps to 61.2 years

3 hours ago

Life expectancy in AIDS-hit South Africa has shot up sharply over the past decade, thanks to life prolonging anti-retroviral (ARVs) treatment, latest estimates from the country's statistics agency showed Thursday.

User comments : 0